Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.48 |
| ▸ | GJB2 | P29033 | 4/20 | 0.41 |
| ▸ | PTN | P21246 | 1/20 | 0.36 |
| ▸ | MDK | P21741 | 1/20 | 0.36 |
| ▸ | BDNF | P23560 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | IGF2R | P11717 | 4/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28111519 | 0.87 | GJB2 (0.44) | CD209GJB2PTNMDKBDNF | |
| SCHEMBL28111520 | 0.87 | GJB2 (0.44) | CD209GJB2PTNMDKBDNF | |
| SCHEMBL19682308 | 0.84 | CD209 (0.42) | CD209GJB2PTNMDKBDNF | |
| SCHEMBL19682243 | 0.83 | CD209 (0.36) | CD209GJB2HPSE | |
| SCHEMBL18653473 | 0.83 | GJB2 (0.50) | GJB2TNFLGALS3MAPK1IGF2R | |
| SCHEMBL18653423 | 0.83 | GJB2 (0.50) | GJB2TNFLGALS3MAPK1IGF2R | |
| SCHEMBL13760997 | 0.83 | GJB2 (0.47) | GJB2TNFMAPK1IGF2RGBA1 | |
| SCHEMBL19453257 | 0.83 | GJB2 (0.40) | CD209GJB2PTNMDKBDNF | |
| SCHEMBL19682306 | 0.81 | GJB2 (0.49) | GJB2TNFMAPK1IGF2RGBA1 | |
| SCHEMBL8686418 | 0.80 | GBA1 (0.53) | GJB2TNFMAPK1IGF2RGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348414-A1 | NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES | WAYNE STATE UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348414-A1 | NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES | ERG28, DDOST, STT3A | CD209 81/4885GJB2 4753/4885PTN 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.